Huan-Rong Lan
Overview
Explore the profile of Huan-Rong Lan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
167
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lan H, Chen M, Yao S, Chen J, Jin K
Int Immunopharmacol
. 2024 Jan;
128:111549.
PMID: 38266449
Immunotherapy has emerged as a revolutionary approach in cancer therapy, and recent advancements hold significant promise for breast cancer (BCa) management. Employing the patient's immune system to combat BCa has...
2.
Lan H, Chen M, Yao S, Chen J, Jin K
Front Immunol
. 2023 Dec;
14:1266450.
PMID: 38111570
Breast cancer (BCa) is known as a complex and prevalent disease requiring the development of novel anticancer therapeutic approaches. Bispecific antibodies (BsAbs) have emerged as a favorable strategy for BCa...
3.
Xu J, Yang M, Lan H, Jin K
Int Immunopharmacol
. 2023 Sep;
124(Pt B):110981.
PMID: 37769534
The Immunoscore (ISc) is an emerging immune-based scoring system that has shown potential in improving the prognostic and therapeutic management of patients with solid tumors. The ISc evaluates the immune...
4.
Lan H, Zhang Y, Han Y, Yao S, Yang M, Xu X, et al.
J Nanobiotechnology
. 2023 Aug;
21(1):247.
PMID: 37528366
Lymph node metastasis is a frequent occurrence in a variety of tumour forms and poses an enormous challenge to cancer treatment. This process is critical to the development of the...
5.
Sun C, Lan H, Fang X, Yang X, Jin K
Front Immunol
. 2022 Apr;
13:770465.
PMID: 35450073
Cancer immunotherapy is exploited for the treatment of disease by modulating the immune system. Since the conventional animal and 2D models insufficiently recapitulate the complex tumor immune microenvironment (TIME) of...
6.
Hu L, Lan H, Huang D, Li X, Jin K
Front Oncol
. 2021 Dec;
11:769305.
PMID: 34888246
Colorectal cancer (CRC) is the second leading cause of cancer death in the world. Immunotherapy using monoclonal antibodies, immune-checkpoint inhibitors, adoptive cell therapy, and cancer vaccines has raised great hopes...
7.
Hu L, Yang X, Lan H, Fang X, Chen X, Jin K
Exp Cell Res
. 2021 Oct;
408(2):112858.
PMID: 34600901
In contrast to conventional cancer treatment, in personalized cancer medicine each patient receives a specific treatment. The response to therapy, clinical outcomes, and tumor behavior such as metastases, tumor progression,...
8.
Hu L, Lan H, Li X, Jin K
Oxid Med Cell Longev
. 2021 Sep;
2021:2951697.
PMID: 34471463
Purpose: Although doxorubicin chemotherapeutic drug is commonly used to treat various solid and hematological tumors, its clinical use is restricted because of its adverse effects on the normal cells/tissues, especially...
9.
Jin K, Du W, Lan H, Liu Y, Mao C, Du J, et al.
Cancer Sci
. 2021 May;
112(7):2592-2606.
PMID: 33938090
Immunotherapy has revolutionized cancer treatment, however, not all tumor types and patients are completely responsive to this approach. Establishing predictive pre-clinical models would allow for more accurate and practical immunotherapeutic...
10.
Lan H, Du W, Liu Y, Mao C, Jin K, Yang X
Int Immunopharmacol
. 2021 Apr;
96:107627.
PMID: 33862552
Breast cancer (BC) is the most common cancer among women between the ages of 20 and 50, affecting more than 2.1 million people and causing the annual death of more...